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Pre-mRNA splicing is a fundamental process in mammalian gene expression and alternative 14 
splicing plays an extensive role in generating protein diversity. Since the majority of genes 15 
undergo pre-mRNA splicing, most cellular processes depend on proper spliceosome function. 16 
Here we focus on the cell cycle and describe its dependence on pre-mRNA splicing and 17 
accurate alternative splicing. We outline the key cell cycle factors and their known alternative 18 
splicing isoforms. We discuss different levels of pre-mRNA splicing regulation such as post-19 
translational modifications and changes in expression of splicing factors. We describe the 20 
effect of chromatin dynamics on pre-mRNA splicing during the cell cycle. In addition, we 21 
focus on the spliceosome component SF3B1, which is mutated in many types of cancer, and 22 
describe the link of SF3B1 and its inhibitors to cell cycle. 23 
24 




Pre-mRNA splicing occurs in 97% of human genes. This suggests that most if not all cellular 25 
processes are dependent on the splicing machinery. Here we focus on the cell cycle process 26 
and discuss its many connections with pre-mRNA splicing. Splicing is regulated by both 27 
splicing factors and chromatin, which are known to alter during the cell cycle. We will review 28 
the changes in these two regulators and their effect on cell cycle.  29 
Cell cycle 30 
The cell-cycle process is highly conserved and precisely controlled to conduct genome 31 
replication. The process consists of four distinct phases, G0/G1, S (DNA synthesis), G2, and 32 
M (mitosis) with multiple checkpoints. These cell cycle checkpoints ensure reliable replication 33 
of the cell’s DNA in the S phase and the exact division of the chromosomes into daughter cells. 34 
Ensuring that all chromosomes are aligned correctly on the mitotic spindle before division of 35 
the two daughter cells prevents dead, aneuploid, or mutant cells. The G1 and G2 phases serve 36 
as gaps between the S and M phases. G1 is the point where the decision is made whether to go 37 
into S phase and replicate the DNA or to exit the cell cycle and go to G0. G2 ensures full 38 
replication of the genome in S phase and the transition to cell division in M phase.   39 
Cell cycle decisions are made by assessing both intra- and extracellular signals. Intracellular 40 
signals are proper replication of the DNA and the correct post-translational modification 41 
pattern of cell cycle proteins. Those proteins are cyclins and cyclin-dependent kinases (CDKs), 42 
which are a group of serine/threonine kinases. They form complexes with cyclins to stabilize, 43 
activate, and phosphorylate key cell cycle factors at specific phases [1]. CDKs’ catalytic 44 
activities are regulated by interactions with cyclins and CDK inhibitors (CKIs). The formation 45 
of cyclin/CDK complexes controls the cell-cycle progression via phosphorylation of the target 46 
genes [2]. 47 
Epigenetic dynamics during cell-cycle progression 48 
Chromatin binding proteins and chromatin modifications are dynamic during the cell cycle and 49 
chromatin impacts cell cycle events such as origin firing, chromosome segregation at mitosis 50 
and gene expression. Chromatin dynamics stem from histone modifiers which fluctuate in 51 
expression and post-translational modifications in a cell cycle-dependent manner [3]. For 52 
example, CDK1 and CDK2 can phosphorylate the chromatin factor, enhancer of zeste homolog 53 
2 (EZH2), in a cell cycle-dependent manner and in turn silence genes during the cell cycle [4]. 54 
Chromatin also plays a large role in correct chromosome segregation by allowing 55 
chromosomes to condensate. This condensation is enabled by phosphorylation of H3 by the 56 
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Aurora B kinase that recruits the Condensin I complexes [5]. In addition, phosphorylation of 57 
H3 modulates the binding of repressive chromatin proteins to mitotic chromosomes [6].  58 
Gene expression during cell-cycle progression 59 
Many proteins that carry out important functions during the cell cycle display a cyclical 60 
expression pattern that is often regulated at the transcriptional level [7-9]. Thus, genes 61 
expressed in specific phases of the cell cycle are different from those expressed at steady-state 62 
[10]. Sensitive methods that identify small amounts of mRNA have identified specific 63 
transcripts expressed at each phase. These methods have also helped identify enhancer RNA 64 
(see Glossary) which indicates the specific enhancers activated during the cell cycle [10]. This 65 
adjusted expression requires a well-orchestrated regulation that also needs to adapt to the 66 
changing amount of DNA in the cell. This is made possible by regulation via chromatin 67 
structure. In addition to change in gene expression, M phase is considered to have less 68 
transcription and translation in general [11]. Interestingly cell-free lysates from mitotic cells 69 
are also less efficient in in vitro pre-mRNA splicing [11]. 70 
Pre-mRNA splicing  71 
97% of human genes harbor introns which are removed in a process called pre-mRNA splicing 72 
[12]. The splicing reaction is catalyzed by the spliceosome, a multi-subunit complex, 73 
comprised of proteins and small noncoding RNAs (U1,U2, U4, U5 and U6) [13-15]. The 74 
spliceosome coordinates two transesterification reactions necessary to remove introns and to 75 
join the adjacent exons. It functions by step-wise formation of sub-complexes that recognize 76 
motif sequences on the pre-mRNA and promote efficient splicing [16].  77 
Adjacent exons are not constitutively spliced together; alternative splicing is a process by 78 
which specific exons are selectively included or excluded [14]. Alternative splicing occurs in 79 
more than 90% of genes and allows for the production of multiple protein isoforms from a 80 
single pre-mRNA molecule by the use of splice sites [17-19]. Each isoform produced can 81 
harbor different functions and so alternative splicing contributes significantly to regulation of 82 
cellular function [20]. The main forms of alternative splicing are exon skipping, intron 83 
retention, alternative 3′ splice site, alternative 5′ splice site, and mutually exclusive exons [21]. 84 
In addition to protein diversity, alternative splicing can also lead to reduced translation of an 85 
mRNA by introduction of a toxic exon or intron which gives rise to a transcript with a 86 
premature stop codon that might undergo nonsense-mediated mRNA decay (NMD) or a 87 
transcript that will be sequestered in the nucleus [22].   88 
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Alternative splicing is frequently regulated by trans-acting factors binding to sequence motifs 89 
that are associated with the enhancing or silencing of pre-mRNA splicing. These motifs can be 90 
found in either exons or introns [13]. They are bound by an array of RNA-binding proteins that 91 
can be divided into two groups; the serine/arginine-rich proteins (SR proteins) and a 92 
heterogeneous group of nuclear ribonucleoproteins (hnRNPs) [23]. SR proteins harbor one or 93 
two RNA recognition motif (RRM) domains at the amino terminus that allow for RNA-binding 94 
specificity and a carboxy-terminal arginine/serine-rich (RS) domain affecting protein–protein 95 
interactions [24]. hnRNPs harbor the RRM domains and unstructured domains that could 96 
regulate their protein–protein interactions [25]. 97 
A major study of pre-mRNA splicing during cell cycle was conducted in human cervical cancer 98 
cells by RNA-seq analysis of synchronously dividing HeLa cells [26]. Dominguez et al. 99 
discovered 1182 genes whose gene expression was altered during the cell cycle and 1293 genes 100 
whose alternative splicing changed during the cell cycle and there was a minor overlap between 101 
these two groups [26]. This study suggested independent regulation of the two processes during 102 
cell cycle. Of all the genes expressed in the HeLa cells studied, 15% had periodic cell cycle-103 
dependent alternative splicing. In addition to a major class of alternative splicing of cassette 104 
exons, sequencing RNA also pointed to intron retention as a key event regulated during cell 105 
cycle [26]. 106 
Since almost all genes undergo splicing it is reasonable to assume that cell cycle progression, 107 
or any other cell process, will be dependent on spliceosome function. Evidence that strengthens 108 
this assumption come from the results of multiple screens searching for novel cell cycle genes, 109 
such as those of Hwang et al. in yeast and Neumann et al. in HeLa cells [27, 28]. These screens 110 
led to the prediction that arrest is a general consequence of interfering with core spliceosome 111 
function; the genes revealed as cell cycle genes in these and further studies are DHX8 [27], 112 
PRPF8 [29, 30], U2AF2 [31], CDC5L [32, 33], DDX46 and PRPF6 [34]. 113 
Since splicing is an essential process in mammalian cells, it can affect the ability of cells to 114 
proliferate by giving rise to a specific alternative spliced isoform [35] and the generation of 115 
specific splicing isoforms has recently been found to act as a driver of cancer [35-39] and can 116 
inhibit apoptosis (reviewed in [40]). In addition, global alterations in splicing arrays in cancer 117 
can be the result of changes in expression of splicing factors that may dictate an oncogenic 118 
splicing pattern [13–16], or by mutations that give rise to a specific splicing isoform with a 119 
potential to promote cancer [12]. In this review we focus on pre-mRNA splicing that affects 120 
the cell cycle directly and thus will not cover proliferation or apoptosis. An additional role for 121 
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some splicing factors is resolving R loops, generated between nascent transcripts and the DNA 122 
while transcription take place. Problems with R loop resolution lead to DNA damage and as a 123 
result halt cell cycle. This indirect effect of splicing factors on cell cycle is also not part of this 124 
review (reviewed in [41]). Many splicing factors have also been found to have additional 125 
functions in mitosis that do not involve pre-mRNA splicing (reviewed in [42]). Here we will 126 
focus on two main intersections between pre-mRNA splicing and cell cycle. The first is the 127 
need for pre-mRNA splicing to allow for production of key factors of the cell cycle that harbor 128 
introns. The second is alternative splicing of those key factors in order to produce the specific 129 
isoform needed for cell cycle progression. In addition, we will detail what is known to date 130 
about the role of splicing factors in the process that occur during the cell cycle. These splicing 131 
factors can be regulated in several ways: 1) by post-translational modifications; 2) at the level 132 
of their expression; 3) and via chromatin. We will review all of these different aspects here. 133 
Pre-mRNA splicing of cell cycle key factors 134 
Cell division cycle 25 (CDC25): Currently the only known targets of the members of the 135 
CDC25 family of phosphatases, CDC25A, B and C, are CDK/cyclin complexes [43, 44]. This 136 
function sets CDC25 as a regulator of all cell cycle stages, as its targets are CDK2/cyclin E at 137 
the G1–S transition and CDK1–cyclin B at the entry into mitosis [45]. Regulation of the 138 
CDC25 family was found to be at the protein level but also via alternative splicing [46-50]. 139 
Not much is known about the role of each of the alternative splicing isoforms or their 140 
regulation, but data exist on the change in phosphatase function [51] and differential protein 141 
stability between CDC25B isoforms [52]. In addition, U2AF1 was shown to be important for 142 
the pre-mRNA splicing of both CDC25B and C [53]. Andersen et al. identified Prp38 or Mfap1 143 
as regulators of CDC25 (named mitotic phosphatase string) in Drosophila cells [54]. Depletion 144 
of PRP38 or MFAP1 led to arrest in G2/M, which might be a result of abnormal splicing of the 145 
CDC25.  146 
Aurora kinase B (AURKB): AURKB is a member of the aurora kinase subfamily of 147 
serine/threonine kinases, part of the chromosomal passenger complex (CPC), and is required 148 
for chromatin-induced microtubule stabilization and spindle assembly. While AURKB has 149 
several coding alternative splicing isoforms, their regulation during the cell cycle is not known. 150 
Lately it was suggested that an intron retention isoform with a premature termination codon is 151 
promoted during S/G2. As a result, nonsense-mediated decay of this isoform leads to reduced 152 
AURKB protein amount following M phase [26]. 153 
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CDC-like kinase 1 (CLK1): CLK1’s role as a kinase of splicing factors will be detailed in the 154 
next section. Alternative splicing regulation of CLK1 exon EB was shown to be important for 155 
its kinase activity [55, 56]. Inclusion of exon EB promotes a catalytically active CLK1. 156 
Interestingly CLK1 auto-regulates its alternative splicing, as the CLK1 isoform with exon EB 157 
promotes exon EB exclusion while the CLK1 isoform without exon EB promotes its inclusion 158 
[55, 56].  159 
CDK2: CDK2 is a serine/threonine protein kinase, which has a role in all cell cycle phases. 160 
CDK2/cyclin E complex contributes to the phosphorylation of the retinoblastoma (RB) protein 161 
which drives the cell to S phase (Figure 1). In late S phase CDK2/cyclin A phosphorylates 162 
different targets to control the cell cycle transition from S to G2. For example, CDK2/cyclin A 163 
phosphorylates CDC6, an initiator of DNA replication. Phosphorylated CDC6 translocates to 164 
the cytoplasm to prevent re-replication of the DNA [57] (Figure 1). Regulation of CDK2 165 
alternative splicing by exclusion of exon 5 represses CDK2 protein expression and thus impacts 166 
cell cycle control [58]. The regulation of CDK2 alternative splicing is coordinated by poly(rC) 167 
binding protein 1 and 2 (PCBP1/2) as well as the splicing factor PTB. PCBP1/2 and PTB 168 
promote CDK2 exon 5 inclusion by binding specifically to the C-rich polypyrimidine tract 169 
splice acceptor 5′ to exon 5 [58] (Figure 1). Thus PCBP1/2 and PTB promote CDK2 protein 170 
stabilization. 171 
Post-translational modifications of splicing factors during cell cycle 172 
Post-translational modifications of splicing factors affect their protein–protein and protein–173 
RNA interactions, intracellular localization, trafficking and activation, thus affecting pre-174 
mRNA splicing as well as alternative splicing. Splicing factor kinases, such as SRSF protein 175 
kinase 1 (SRPK1) [59, 60], SRPK2 [61] and CLK1 [26], were shown to change in expression 176 
during the cell cycle to phosphorylate their targets in a way that is dependent on cell cycle 177 
phase.  178 
Nuclear speckles provide storage for splicing factors with no or few post-translational 179 
modifications. Nuclear speckles break down and reform as cells progress through mitosis 180 
(Figure 2); this dynamic phenomenon was first shown to be dependent on SRPK1 in HeLa cells 181 
[59, 60, 62, 63] and later to be shared with its homologue SRPK2 in various human cells lines 182 
and tissues [61]. SRPKs are more active during M phase, leading to nuclear speckle 183 
disassembly by phosphorylating splicing factors [64]. Cell cycle-dependent phosphorylation 184 
of splicing factors by SRPK1 during M phase was first identified in HeLa cells by the use of a 185 
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radioactive isotope of phosphorus (32P) [64]. SRSF1, SRSF2, SRSF3 and SRSF6 splicing 186 
factors were shown in HeLa cells to be phosphorylated by SRPK1, but the phosphorylation 187 
was not directly connected to cell-cycle regulation. At M phase exit there is reconstitution of 188 
the nuclear envelope, and most pre-mRNA splicing factors gradually self-organize to reform 189 
the nuclear speckle [62].  190 
One of the first functions discovered for splicing factor phosphorylation during cell cycle was 191 
change in activity [11, 65]. SRSF10 serves as a splicing repressor in its unphosphorylated state, 192 
while in its phosphorylated state it is a sequence-specific splicing activator [66]. Although PP1 193 
was demonstrated to dephosphorylate SRSF10 following heat shock, it is not known if it is the 194 
same phosphatase acting during cell cycle [67].  195 
CLK1 expression level oscillates during the cell cycle promoting auto-phosphorylation that 196 
leads to its stabilization and peak expression at G2/M [26, 68]. CLK1’s role as a splicing factor 197 
kinase [69, 70] is predicted to be the cause of its prominent regulation of alternative splicing 198 
during cell cycle and was found to be the central cause of most alternative splicing regulation 199 
[26]. Thus, silencing or inhibiting CLK1 leads to late S-phase/G2 phase arrest. 200 
Phosphorylation of the splicing factor SRSF1 was shown in HeLa cells to regulate its function 201 
in pre-mRNA splicing [71] and to lead to a change in its subcellular localization in pediatric 202 
acute lymphoblastic leukemia cells [72]. In detail, phosphorylation on Tyr-19 by kinase TIE2 203 
allowed cell cycle entry [72]. Furthermore mutating Tyr-19 resulted in cell‐cycle arrest in the 204 
G0/G1 phase [72], while depleting DT40 cells of SRSF1 led to G2 cell cycle arrest [73]. The 205 
M-phase promoting factor, CDK1, phosphorylates SRSF1 on its RS domain on serines 227 and 206 
238 in a cell cycle-dependent manner during G2/M phase [74], while this phosphorylation 207 
probably has merit in cell cycle regulation, it has never been demonstrated, nor has SRSF1 208 
phosphorylation by SRPK2 [61, 75].  209 
One of the major splicing factors studied in connection to cell cycle regulation is cell division 210 
cycle 5-like protein (CDC5L), also known as CDC5, which is part of the Prp19 complex, a 211 
component of the pre-mRNA splicing complex. CDC5L was shown to be essential for pre-212 
mRNA splicing from yeast to humans [76-84]. Since CDC5L is expressed constitutively 213 
throughout the cell cycle [85], it was suggested that it is regulated via post-translational 214 
modification. Indeed it was shown that CDC5L is phosphorylated by CDK2 in a mitogen-215 
dependent manner in monkey COS-7 cells and that its phosphorylation in murine RRC285 cells 216 
and human HeLa cells is critical to its association with the spliceosome [86, 87]. Furthermore, 217 
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it was found in vitro using rat liver nuclear extracts that phosphorylation of CDC5L by 218 
CDK2/cyclin E is required for CDC5L binding to the nuclear RNA binding protein, NIPP1 219 
[87] (Figure 1). Depletion of CDC5L causes dramatic mitotic arrest, chromosome 220 
misalignments and sustained activation of spindle assembly checkpoint [85, 88-90]. The 221 
mechanism can be inferred from data showing that CDC5L modulates the pre-mRNA splicing 222 
of a set of genes involved in mitosis [89]. One of these genes is α-TUBULIN, which can rescue 223 
CDC5L mutations by deleting its intron [91]. This suggests that CDC5L’s role as a splicing 224 
regulator is needed for proper cell cycle regulation. However, recent evidence suggests that 225 
CDC5L has a direct role as a cell cycle component. CDC5L was shown in human HeLa and 226 
HCT-116 cells to bind the cell‐cycle checkpoint kinase ataxia‐telangiectasia and Rad3‐related 227 
(ATR) and is important for the phosphorylation of its targets such as checkpoint kinase 228 
1(CHK1), cell cycle checkpoint protein Rad 17 (RAD17) and Fanconi anaemia 229 
complementation group D2 protein (FANCD2) [92]. Blocking of replication fork in the latter 230 
study resulted in cell cycle arrest at the S phase, positioning phosphorylation by CDC5L as a 231 
regulator of S phase [92]. It could be that CDC5L regulates cell cycle via splicing regulation 232 
in the absence of DNA damage, and in addition has a direct role in cell cycle following DNA 233 
damage. 234 
Interestingly the splicing factor CDC40’s effect on cell cycle may also be rescued by intron- 235 
less α‐TUBULIN. Saccharomyces cerevisiae CDC40 encodes a second‐step pre‐mRNA 236 
splicing factor with a role in cell division [93-97]. The transitions from G1/S and G2/M are 237 
regulated by CDC40 as it participates in the splicing of key regulators of cell cycle such as α‐238 
TUBULIN [98] and ANC1 [99]. Rescue of cell-cycle arrest in yeast was enabled by genomic 239 
replacement with an intronless form of these genes [98, 99].  240 
Change in expression of splicing factors during the cell cycle 241 
Differential expression of a splicing factor in a specific cell cycle phase can alter pre-mRNA 242 
splicing to allow for a proper cell cycle progression. Looking at all RNA binding proteins 243 
genome wide using RNA-seq, Dominguez et al. found 96 RNA binding proteins that oscillate 244 
during the cell cycle [26]. The RNA binding proteins were enriched for a function in pre-245 
mRNA splicing and included the RS domain-containing factors SRSF2, SRSF8, TRA2A and 246 
SRSF6. These splicing factors were shown to change in expression but it is not clear how they 247 
directly regulate cell cycle. 248 
An example of a splicing factor regulated in expression through a cell cycle-dependent manner 249 
is Wilms tumor 1-associating protein (WTAP). WTAP protein amount in human umbilical vein 250 
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endothelial cells (HUVECs) was found to be low in G1 and increased to reach its peak in G2/M. 251 
WTAP high expression in G2/M correlated with that of CYCLIN A2 and it was shown in 252 
HUVECs to stabilize its mRNA through its 3’ UTR sequence [100]. WTAP is localized 253 
throughout the nucleoplasm as well as in the nuclear speckles and partially colocalizes with 254 
splicing factors in HUVECs [101]. WTAP also binds to the RNA processing factors THRAP3 255 
and BCLAF1 and this binding was shown to be critical to its localization to nuclear speckles 256 
[101]. Interestingly, THRAP3 and BCLAF1 regulate pre-mRNA splicing of genes involved in 257 
cell cycle regulation [102].  258 
Another splicing factor with differential expression in cell cycle is RBM42 (TgRRM1) [103]. 259 
RBM42 was identified in the Toxoplasma parasite and its expression was found to be highest 260 
in late M and early G1. RBM42 binds the spliceosome components snRNA U4, U5 and U6 261 
and is critical to the pre-mRNA splicing process. A point mutation in RBM42 in Toxoplasma 262 
led to G1 arrest with cell cycle regulation by RBM42 speculated to occur due to its role as a 263 
pre-mRNA splicing factor [103].   264 
Chromatin alteration during cell cycle and its effect on alternative splicing 265 
Recent evidence points to a contribution of epigenetic marks and higher order chromatin 266 
structure to alternative splicing regulation [104]. Moreover, genome-wide mapping has 267 
revealed enrichment of nucleosomes in exons [105, 106]. In addition, several histone 268 
modifications are enriched in exons relative to introns and numerous modifications, such as 269 
H3K36me3, are differentially associated with constitutive exons relative to alternative ones 270 
[107]. Since chromatin is dynamic during the cell cycle, it is possible that it serves as a regulator 271 
of alternative splicing.  272 
The three histone modifications H3K36me3, H3K27ac, and H4K8ac mark alternatively spliced 273 
exons [108]. This was observed by following chromatin and alternative splicing states in 274 
human embryonic stem cells relative to differentiated cells. More than half of alternative 275 
splicing genes regulated by H3K36me3, H3K27ac, and H4K8ac are enriched for genes with 276 
function in G2/M cell-cycle phases [108]. Interestingly the effect of the histone modifications 277 
on alternative splicing was suggested to be mediated via transcription factors with a known 278 
role in cell differentiation [108].  279 
A recent study identified the histone demethylase KDM3A as a regulator of alternative 280 
splicing during cell cycle [109]. RNA-seq following silencing of KDM3A revealed a group of 281 
genes with a role in cell cycle. Interestingly, KDM3A is a regulator of both transcription and 282 
10 
 
alternative splicing, but acting independently, as the expression and alternative splicing genes 283 
formed two separate groups.  KDM3A was found to be necessary for the binding of the splicing 284 
factor SRSF3 to pre-mRNA. Silencing either KDM3A or SRSF3 promoted a higher percentage 285 
of cells in S-phase. Furthermore, this study indicated that alternative splicing of a target of 286 
KDM3A, the cell cycle gene SAT1, is the mediator between KDM3A and cell cycle regulation. 287 
Finally, these findings suggest that change in chromatin during the cell cycle can promote 288 
regulation of alternative splicing of genes important to this process.   289 
SF3B1 and its splicing inhibitors role in cell cycle 290 
The spliceosome component SF3B1 binds and stabilizes the small nuclear RNA (snRNA) U2. 291 
U2 binding to the branch point site is important for splice site recognition [110, 111]. The 292 
binding of the complex bulges out the adenosine at the branch point to facilitate the first 293 
catalytic reaction in the splicing cycle [112]. In addition, SF3B1 allows the identification of 294 
short exons flanked by long introns with differential GC content by binding to the exons’ 295 
nucleosomes [113] (Figure 3). Both functions of SF3B1 rely on its phosphorylation at several 296 
sites. SF3B1 phosphorylation was also found to be cell cycle dependent. One SF3B1 kinase 297 
identified is dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), which 298 
phosphorylates it on its Thr434 site [114, 115]. In addition, the G1 phase complex CDK2/cyclin 299 
E phosphorylates SF3B1on Thr313 and this specific phosphorylation was shown to be critical 300 
for active splicing [116]. Many more possible phosphorylation sites are located mainly at its N 301 
terminal domain. Murthy et al. demonstrated cell cycle-dependent phosphorylation of SF3B1 302 
[117]. This study suggested that nucleosome binding of SF3B1 is dynamic as a result of its 303 
phosphorylation and thus regulates alternative splicing of cell cycle genes. In detail, SF3B1 304 
phosphorylation peaks at G2/M in a CDK1-dependent manner, and then decreases due to PP2A 305 
and PP1 phosphatase activities, as the cell progresses through G1/S [117] (Figure 3). Notably, 306 
SF3B1 binding to nucleosomes increases during G1/S when it has the lowest phosphorylation 307 
level. In a complementary manner, the interaction with nucleosomes is greatly diminished 308 
during G2/M, when the phosphorylation level is higher [117] (Figure 3).  309 
The link of SF3B1 to cell cycle progression gained attention due to the elevated levels of SF3B1 310 
mutants in several types of cancers such as myelodysplastic syndrome (MDS), chronic 311 
lymphocytic leukemia, uveal and breast cancer [118-121]. How these mutations result in cancer 312 
is not yet fully understood. However, a few studies have shown that SF3B1 mutations lead to 313 
the use of cryptic 3`-splice sites upstream of the canonical one and to the promotion of the 314 
selection of an alternative branch point [122-125]. Kesarwani et al. showed in human 315 
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transfected K562 cells and in cells derived from MDS patients, that these cryptic splice sites 316 
are detectable by the spliceosome because of a structural change that suffers upon the inclusion 317 
of a mutated SF3B1 subunit [126]. The effect of these events is an altered splicing pattern of a 318 
large list of genes related to cell cycle [127, 128]. In another study the disruption of SF3B1 319 
induced a significant downregulation of pathways related to cell cycle regulation and led to G1 320 
and G2 arrest in human MDS stem and progenitor cell lines (TF1, K562, HEL and SKM1) 321 
[129].  322 
Huang et al. showed that the knockdown of SF3B1 in human erythropoietic cells caused early 323 
cell cycle arrest by the activation of the p53 pathway due to an isoform switch of E3 ligase 324 
makorin ring finger protein 1 (MKRN1) and downregulation of genes involved in mitosis and 325 
cytokinesis [130]. In loss-of-function zebrafish mutants, erythrocytes also presented with 326 
G0/G1 arrest [131]. Here, SF3B1’s effect was suggested to cause elevated expression of 327 
transforming growth factor β (TGFβ) and decreased expression of cell cycle genes [131].  328 
A significant tool to study the role of SF3B1 in cell cycle are its many inhibitors (reviewed in 329 
[132]). All SF3B1 inhibitors studied have demonstrated anti-tumoral properties [110, 133-136] 330 
and a common pharmacophore model by which their specific interaction with SF3B1 provokes 331 
a conformational change and leads to splicing alteration due to a branch point recognition 332 
disturbance [111, 132, 137]. The fact that cells with SF3B1 inhibition or downregulation leads 333 
to similar aberrant splicing patterns suggest that affected genes share similarities at the 3`splice 334 
site and weak branch point sites [126-128, 132]. Interestingly each of the SF3B1 inhibitors can 335 
have a different effect on cell cycle [138]. Pladienolide B can lead to early (G1) as well as late 336 
(G2/M) arrest in two erythroleukemia cell lines, HEL and K562 [139], while isoginkgetin 337 
provokes slowdown of multiple phases in the cell cycle (G1, S and G2) but not M phase in 338 
human colon HCT116 cells and ovarian cancer A2780 cells [140]. A detailed investigation of 339 
the effect of spliceostatin A found reduced cell proliferation in HeLA cells due to decreased 340 
expression of cell cycle genes such as CYCLIN A2 and AURORA A KINASE [111]. The 341 
mechanism that leads to the change in expression was suggested to be mediated by 342 
nonproductive pre-mRNA splicing. In a study using four types of human cells, HeLa, Rh18, 343 
HEK293 and primary fibroblasts, it was found that  Sudemycin E inhibits SF3B1 binding to 344 
nucleosomes. Diminished H3K36me3 mark in these nucleosomes was also detected and cell 345 
cycle arrest was observed (G2 phase) [141]. We have described here various cell cycle 346 
alterations by SF3B1; these diverse and sometimes contradicting effects might stem from its 347 
differential expression in different cell types with diverse genetic backgrounds [142, 143]. 348 
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Concluding Remarks  349 
There is an increasing awareness of the importance and potential of pre-mRNA splicing in 350 
disease and therapy. Furthermore, alternative splicing is of great physiological relevance as it 351 
enables the production of multiple protein isoforms from a single pre-mRNA molecule by the 352 
combinatorial use of splice sites. The various protein isoforms produced can have different 353 
functions and as such alternative splicing contributes significantly to regulation of cellular 354 
function. Here we focus on the novel, and very exciting, insights into the emerging field of 355 
splicing modulation during the cell cycle. 356 
The exact splicing patterns in each of the cell cycle phases is yet to be rigorously characterized. 357 
In the future combining this data with the different levels of alternative splicing regulation 358 
described here, namely splicing factor expression; post-translational modification and 359 
chromatin dynamics, can set the path to a deeper understanding of alternative splicing 360 
regulation in cell cycle and beyond (see Outstanding Questions box). 361 
 362 
Figure Legends 363 
Figure 1: Alternative splicing of CDK2 is regulated in order to phosphorylate splicing 364 
factors important for cell cycle progression. A. PCBP1/2 and PTB bind the 5’ splice site of 365 
CDK2 exon 5 (dark red rectangle) to promote its inclusion. CDK2 exon 5 inclusion gives rise 366 
to a more stable protein serving as a more potent kinase. B. The CDK2/cyclin E complex 367 
phosphorylates retinoblastoma (RB) protein to drive the cell to S phase. In late S phase 368 
CDK2/cyclin A phosphorylates CDC6 to allow for exit from S phase. Finally CDK2/cyclin E 369 
phosphorylates the splicing factor CDC5L, which regulates the splicing of many genes 370 
involved in cell cycle. 371 
Figure 2: Nuclear speckles are stable during interphase and disperse during early 372 
metaphase. Cellular localization of the nuclear speckle marker SRSF2 in HeLa cells at 373 
different cell cycle stages. Arrow heads denote splicing speckles. Scale bar 6.5 µm. 374 
Figure 3: The spliceosome component SF3B1 is essential for cell cycle progression. SF3B1 375 
phosphorylation peaks at G2/M in a CDK1-dependent manner, and then decreases due to PP2A 376 
and PP1 phosphatase activities as the cell progresses through G1/S. SF3B1 in its 377 
unphosphorylated state allows the identification of short exons flanked by long introns by 378 
binding to the exons’ nucleosome. SF3B1 binding to nucleosomes allow for alternative splicing 379 
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Chromosomal passenger complex (CPC): This functions at the centromere to ensure 706 
correct chromosome alignment and segregation. 707 
Enhancer RNA: short non-coding RNA molecules (50-2000 nucleotides) transcribed from 708 
the DNA sequence of enhancer regions which have a role in transcriptional regulation. 709 
Histone demethylase: An enzyme that removes methyl (CH3-) groups from histones that is 710 
important in epigenetic modification mechanisms. Histone demethylases alter transcriptional 711 
regulation of the genome by controlling the methylation levels that occur on histones and so 712 
regulate the chromatin state at specific gene loci within organisms. 713 
23 
 
Nuclear speckles: nuclear domains enriched in pre-mRNA splicing factors, located in the 714 
interchromatin regions of the nucleoplasm of mammalian cells. 715 
Nucleosomes: the basic structural unit of DNA packaging in eukaryotes consisting of a 716 
segment of DNA wound around eight histone proteins. It is the fundamental subunit of 717 
chromatin.  718 
R loop: a three-stranded nucleic acid structure, composed of a DNA:RNA hybrid and the 719 
associated non-template single-stranded DNA, formed in a variety of circumstances. The 720 
presence of R-loops can inhibit transcription and R-loop formation appears to be associated 721 
with “open” chromatin, characteristic of actively transcribed regions. 722 
Small nuclear RNA (snRNA): a class of small RNA molecules of around 150 nucleotides 723 
that are found within the splicing speckles and Cajal bodies of the cell nucleus in eukaryotic 724 
cells. Their primary function is in the processing of pre-messenger RNA (hnRNA) in the 725 
nucleus. 726 
Unstructured domains: also called auxiliary domains, these are proline-, glycine- or acid-727 
rich. These domains are speculated to provide the specificity of the RNA binding domain in 728 
the hnRNP protein family. This is facilitated by the 3D structure of the protein around the 729 
RNA binding domains which fine-tunes the RNA–protein interaction. 730 
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